Idera Pharmaceuticals, Inc.
(NASDAQ : IDRA)

( )
IDRA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading IDRA News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.31%72.131.0%$655.07m
AMGNAmgen Inc.
0.63%155.770.8%$509.15m
CELGCelgene Corporation
0.24%115.221.0%$465.18m
ARIAARIAD Pharmaceuticals, Inc.
0.23%23.7016.4%$416.43m
BIIBBiogen Inc.
0.21%283.611.0%$405.76m
ALXNAlexion Pharmaceuticals, Inc.
0.42%135.872.5%$385.05m
REGNRegeneron Pharmaceuticals, Inc.
-0.08%362.952.5%$365.07m
ILMNIllumina, Inc.
0.47%161.233.8%$225.12m
CLVSClovis Oncology, Inc.
0.64%56.6217.9%$166.73m
VRTXVertex Pharmaceuticals Incorporated
1.19%82.522.1%$152.50m
INCYIncyte Corporation
1.28%115.092.2%$149.42m
SRPTSarepta Therapeutics, Inc.
-0.42%35.9816.8%$110.90m
ACADACADIA Pharmaceuticals Inc.
3.06%32.3118.3%$110.16m
IONSIonis Pharmaceuticals, Inc.
1.12%47.148.9%$110.11m
TSROTESARO, Inc.
-1.32%149.2615.0%$109.40m

Company Profile

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. The company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. Idera Pharmaceuticals was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.